Atosiban (CAS 90779-69-4) is a high-purity oxytocin receptor antagonist API, a non-peptide compound designed for the prevention and treatment of preterm labor. With a precise molecular structure, it acts by competitively binding to oxytocin receptors on uterine smooth muscle cells, thereby inhibiting uterine contractions. This mechanism effectively delays the onset of labor and prolongs gestation, reducing the risk of preterm birth complications and improving fetal outcomes.
Produced under strict GMP standards, this API ensures consistent purity (≥99%) and stability, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for the management of preterm labor, catering to the needs of pharmaceutical manufacturers and research institutions in the field of obstetrics and gynecology.
Its unique ability to selectively block oxytocin receptors provides precise control over uterine activity, making it a preferred choice for clinical use. Atosiban delivers reliable therapeutic benefits with a favorable safety profile, supporting the development of effective treatments for preterm birth.
